Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

Status Recruiting

Clinical Trial Summary

This study seeks to determine the safety and efficacy of shortening the primary and nodal adjuvant radiation therapy course from 2 Gy x 25 fractions to 3.6 Gy x 10 fractions in merkel cell carcinoma patients who may or may not be receiving immunotherapy.

Clinical Trial Description

- To estimate the 2-year local control rate for adjuvant hypofractionated RT to the primary tumor bed. - To estimate the 2-year nodal control rate for adjuvant hypofractionated RT to the primary draining nodal basin. Secondary Objectives - To determine MCC disease outcomes including:time to non-nodal locoregional recurrence, time to nodal recurrence, time to distant mestasis, disease-free-survival and disease-specific survival for patients receiving hypofractionated adjuvant RT. - To assess acute and late RT associated toxicity within or neighboring the radiated field. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05100095
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact	Devarati Mitra
Phone	(713) 563-1339
Email	dmitra@mdanderson.org
Status	Recruiting
Phase	Phase 2
Start date	December 14, 2021
Completion date	September 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT02978625` - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Not yet recruiting	`NCT04705389` - SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines	N/A
Recruiting	`NCT03212404` - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	Phase 1
Recruiting	`NCT05429866` - Immunological Variables Associated to ICI Toxicity in Cancer Patients	Phase 2
Completed	`NCT03545334` - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study	N/A
Recruiting	`NCT04260802` - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers	Phase 1/Phase 2
Recruiting	`NCT04291885` - Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma	Phase 2
Terminated	`NCT02054884` - F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma	Phase 2
Recruiting	`NCT04975152` - Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma	Phase 1
Not yet recruiting	`NCT06039033` - Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
Completed	`NCT02514824` - MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT04393753` - Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1	Phase 2
Recruiting	`NCT06056895` - Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma	Phase 2
Recruiting	`NCT03370861` - How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Suspended	`NCT04916002` - A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer	Phase 2
Recruiting	`NCT03210935` - French National Database of Rare Dermatological Cancers
Active, not recruiting	`NCT04116320` - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06086288` - Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)	Phase 2